세계의 체외 독성 시험 시장 : 제품 및 서비스, 종말점 및 시험, 기술, 방법, 산업별 예측(2024-2032년)

In-vitro Toxicology Testing Market size is predicted to expand at over 7.7% CAGR from 2024 to 2032, mainly led by the increasing adoption of in-vitro methods over animal testing due to ethical concerns and regulatory pressures. The rising awareness about the adverse effects of chemicals on human health and the developments in cell culture technologies are accelerating the appeal of in-vitro testing.

Lately, there has been growing emphasis on safety assessment during drug development and chemical risk assessment in various industries, such as pharmaceuticals, cosmetics, and chemicals. The availability of funding for research in toxicology and the development of high-throughput screening assays will further increase the utilization of in-vitro toxicology testing solutions. For instance, in August 2023, Altis Biosystems launched RepliGut(R) Planar InflammaScreen(TM) Services to enhance drug discovery for inflammatory bowel diseases (IBD) using a human-derived in vitro model of colon inflammation.

The in-vitro toxicology testing industry is segregated into product and services, endpoint and test, technology, method, industry, and region.

With respect to product and services, the market size from the assays segment will rise at 8% growth rate from 2024 to 2032, on account of the increasing demand for high-throughput screening assays. Rising advancements in assay technologies are allowing for more accurate and reliable results. The growing focus on developing specialized assays for specific toxicological endpoints will increase the penetration of in-vitro testing. The availability of a wide range of assay kits and services tailored to different applications will also drive the segment growth.

In terms of endpoint and test, the in-vitro toxicology testing industry from the genotoxicity segment is anticipated to rise at 8% CAGR from 2024 to 2032. This is due to the advancements in genotoxicity testing methods, increased regulatory scrutiny on genotoxic compounds in various industries, and the growing awareness about the potential hazards associated with genotoxic substances. The development of novel assays and testing strategies for assessing genotoxicity will also increase the demand for in-vitro testing in genotoxicity testing.

Regionally, the Asia Pacific in-vitro toxicology testing market will depict 8.2% growth rate during the projected timeframe. This can be attributed to the increasing industrialization, rising awareness about the importance of toxicity testing in drug development and chemical safety assessment, as well as stringent regulatory guidelines for product safety. The growing R&D activities in pharmaceutical and biotechnology sectors along with the expanding healthcare infrastructure will stimulate the adoption for in-vitro toxicology testing solutions in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast calculations
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rise in government funding for toxicology research
    • 3.2.1.2 Increased R&D investments
    • 3.2.1.3 Technological advancements
    • 3.2.1.4 Growing resistance against animal testing
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory restrictions
    • 3.2.2.2 Lack of in-vitro models to study complex end-points
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutes
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product and Services, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Consumables
• 5.3 Assays
  • 5.3.1 Bacterial toxicity assays
  • 5.3.2 Enzyme toxicity assays
  • 5.3.3 Cell-based ELISA and western blots
  • 5.3.4 Receptor binding assays
  • 5.3.5 Tissue culture assays
  • 5.3.6 Others assays
• 5.4 Equipment
• 5.5 Software
• 5.6 Services

Chapter 6 Market Estimates and Forecast, By Endpoint and Test, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Absorption, distribution, metabolism, and excretion (ADME)
• 6.3 Skin irritation, corrosion, sensitization
• 6.4 Genotoxicity
• 6.5 Cytotoxicity
• 6.6 Ocular toxicity
• 6.7 Organ toxicity
• 6.8 Phototoxicity
• 6.9 Dermal toxicity
• 6.10 Other endpoints and tests

Chapter 7 Market Estimates and Forecast, By Technology, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Cell culture
• 7.3 High throughput
• 7.4 Toxicogenomics

Chapter 8 Market Estimates and Forecast, By Method, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Cellular assays
• 9.3 Biochemical assays
• 9.4 In silico models
• 9.5 Ex vivo models

Chapter 9 Market Estimates and Forecast, By Industry, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Pharmaceuticals and biopharmaceuticals
• 8.3 Cosmetics and household products
• 8.4 Food
• 8.5 Chemicals

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Abbott Laboratories
• 11.2 Agilent Technologies, Inc.
• 11.3 Bio-Rad Laboratories, Inc.
• 11.4 Catalent, Inc.
• 11.5 Charles River Laboratories International, Inc.
• 11.6 Danaher Corporation
• 11.7 Eurofins Scientific
• 11.8 Evotec S.E.
• 11.9 Laboratory Corporation of America Holdings
• 11.10 Merck KGaA
• 11.11 Quest Diagnostics Incorporated
• 11.12 SGS Societe Generale de Surveillance SA
• 11.13 Thermo Fisher Scientific Inc.